Table 1.
Patient Profiles
| Study [n (%)] | Control [n (%)] | All [n (%)] | p Value | |
|---|---|---|---|---|
| Patients | 35 | 35 | 70 | |
| Age | 0.918 | |||
| Mean (SD) | 61.5 (9.8) | 61.2 (13.0) | 60.9 (11.6) | |
| Median (range) | 61 (40–79) | 61 (24–83) | 60.5 (24–83) | |
| Gender | 1.000 | |||
| Male | 13 (37.1%) | 13 (37.1%) | 26 (27.1%) | |
| Female | 22 (62.9%) | 22 (62.9%) | 44 (62.9%) | |
| Primary tumor site | 0.788 | |||
| Right | 10 (28.6%) | 9 (25.7%) | 19 (27.1%) | |
| Left | 25 (71.4%) | 26 (74.3%) | 51 (72.9%) | |
| Metastatic site | 0.812 | |||
| Liver | 13 (37.1%) | 14 (40.0%) | 27 (38.6%) | |
| Lung | 6 (17.1%) | 3 (8.6%) | 9 (12.9%) | |
| Distant lymph nodes | 3 (8.6%) | 5 (14.3%) | 8 (11.4%) | |
| Bone | 1 (2.9%) | 2 (5.7%) | 3 (4.3%) | |
| Other | 3 (8.6%) | 4 (11.4%) | 7 (10.0%) | |
| Multiple | 9 (25.7%) | 7 (20.0%) | 16 (22.9%) | |
| ECOG performance status | 0.003 | |||
| 0 | 4 (11.4%) | 15 (42.9%) | 19 (27.1%) | |
| 1 | 31 (88.6%) | 20 (57.1%) | 51 (72.9%) | |
| KRAS status | 0.001 | |||
| Wild | 9 (25.7%) | 22 (64.7%) | 31 (44.9%) | |
| Mutant | 26 (74.3%) | 12 (35.3%) | 38 (55.1%) | |
| BRAF status | 0.163 | |||
| Wild | 33 (97.1%) | 30 (88.2%) | 63 (92.6%) | |
| Mutant | 1 (2.9%) | 4 (11.8%) | 5 (7.4%) | |
| No data | 1 | 1 | 2 | |
| UGT1A1 status | 0.314 | |||
| Wild (6/6) | 25 (71.4%) | 27 (77.1%) | 52 (74.3%) | |
| Mutant (6/7) | 10 (28.6%) | 8 (22.9%) | 18 (25.7%) | |
| EGFR status | 0.484 | |||
| Positive | 35 (100.0%) | 34 (7.1%) | 69 (98.6%) | |
| Negative | 0 (0.0) | 1 (2.9%) | 1 (1.4%) |
Abbreviations: SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.